Company Overview

VBL Therapeutics is a clinical-stage biotechnology company using its unique scientific platforms and drug development capabilities to fight immune-inflammatory diseases and cancer. Because these serious and sometimes life-threatening diseases are inadequately addressed by current therapies, VBL is committed to developing novel treatments that address this unmet need.

VBL Therapeutics pioneered the Lecinoxoid class of novel, oral anti-inflammatory agents. VB-201, the lead candidate from this program, has strong potential as a specific, targeted oral disease-modifying agent for the control of chronic inflammatory disorders via highly selective modulation of innate immunity. In pre-clinical and Phase 1 studies, VB-201 has been shown to specifically modulate patients’ immune systems, thereby demonstrating its potential to reduce the frequency and severity of flare-ups and avoid the adverse events associated with treatments that systemically target the immune system.

VBL has recently completed Phase 2 clinical trials of its lead compound, VB-201, for the treatment of patients with psoriasis and inflammation in atherosclerosis. Data are expected to be announced in the first half of 2012. Preclinical studies indicate that VB-201 also has significant potential to treat inflammation across other chronic inflammatory diseases including rheumatoid arthritis, atherosclerosis, inflammatory bowel disease and multiple sclerosis.

VBL Therapeutics’ proprietary award-winning Vascular Targeting System (VTS™) technology platform has yielded VB-111, a highly targeted anti-angiogenic agent for the specific inhibition of tumor vascular growth. VB-111 has successfully completed Phase 1/2 single dose clinical trials in cancer patients, and has recently entered Phase 2 clinical trials in thyroid cancer and glioblastoma.

The VBL was founded in 2000 and is based in Tel Aviv, Israel. The company has more than 70 granted patents and more than 110 applications pending.